Pathological complete response after neoadjuvant chemotherapy was associated with lower recurrence risk and higher overall survival in breast cancer patients. The association between pCR and outcomes was similar among those who received additional adjuvant chemotherapy versus those who did not.
A retrospective study found that patients with triple-negative breast cancer who delayed starting adjuvant chemotherapy had a significantly higher risk of disease recurrence and death. The study suggests that initiating chemotherapy within 30 days after surgery is crucial for improving disease-free and overall survival rates.
A randomized clinical trial found immunotherapy drug pembrolizumab more effective than standard chemotherapy in treating chemotherapy-resistant head and neck cancer. Patients receiving pembrolizumab had a higher response rate with longer-lasting responses compared to those on standard therapy.
Researchers have discovered that dasatinib sensitizes triple negative breast cancer cells to chemotherapy by targeting breast cancer stem cells. Additionally, a systematic review and meta-analysis found an increased risk of second cancers at sites associated with HPV after a prior HPV-associated malignancy.
Purdue University researchers have developed a technology that uses nanoparticles to target cancerous cells and tumors, providing more effective and safer chemotherapy treatment. The method has been tested on breast cancer and melanoma models and shows promise for treating various types of cancerous tumors.
A new Northwestern Medicine study reveals a 'kill code' embedded in every cell that can trigger the self-destruction of cancerous cells. The toxic small RNA molecules can also be triggered by chemotherapy, offering a potential bulletproof treatment against cancer.
A phase III clinical trial found immunotherapy pembrolizumab to be more effective than aggressive chemotherapy as a first-line treatment for advanced head and neck cancer. Patients with high PD-L1 levels saw significant improvements in survival and response rates.
A phase II/III study found that a high concentration of multi-strain probiotic helped reduce mild to moderate episodes of chemotherapy-induced diarrhoea (CID) in cancer patients. The probiotic also reduced levels of inflammatory markers, although it did not meet its primary endpoint.
SLU scientist Daniela Salvemini is studying chemotherapy-induced cognitive impairment and opioid addiction to develop new treatments. Her research aims to identify novel therapeutic approaches to mitigate chemo-brain and improve quality of life for cancer patients.
A Phase III clinical trial shows that combining immunotherapy with chemotherapy improves progression-free and overall survival for patients with triple-negative breast cancer. The study's results establish a new standard of care in PD-L1+ patients and provide hope for those diagnosed with this aggressive form of breast cancer.
A combination of immunotherapy and chemotherapy significantly extends survival by up to ten months in patients with triple-negative breast cancer. The treatment reduces the risk of death or cancer progression by up to 40 per cent, offering new hope for young women affected by this aggressive form of breast cancer.
A study of oesophagogastric cancer patients found women experienced higher rates of nausea, vomiting, diarrhoea, mouth ulceration, and hair loss compared to men. The researchers analyzed data from four randomised trials involving over 1,600 patients.
A new blood test that detects circulating tumour DNA is being tested to determine if cancer patients need chemotherapy after surgery. The trial aims to identify high-risk patients who may benefit from aggressive treatment and low-risk patients who can avoid chemotherapy.
Scientists at University of Toronto's Leslie Dan Faculty of Pharmacy have developed a combination approach using nanoparticles to improve chemotherapy response and boost anti-tumor immunity in breast cancer. The treatment resulted in a 60% cure rate and enhanced life expectancy by five-fold compared to treating with chemotherapy alone.
Researchers have developed a gel-based chemotherapy that can shrink melanoma skin tumors in mice by penetrating deep into the skin. The gel, called transfersome, was found to slow tumor growth when applied daily and administered intravenously every other day, with results showing a significant reduction in tumor size.
Researchers at McMaster University have identified a previously unknown cell population that triggers the return of acute myeloid leukemia after remission. This discovery provides a potential new target for therapies and offers hope for improving treatment outcomes for patients with leukemia.
A Moffitt Cancer Center research team compared chemotherapy regimens and found that a combination called ddMVAC was associated with higher complete response rates and improved survival rates compared to standard care. The study analyzed data from over 800 surgical patients with advanced bladder cancer.
Researchers at University of Illinois Chicago discovered that a mutation in the NPM1 gene helps improve sensitivity to chemotherapy in patients. The study found that patients with this mutation tend to respond better to chemotherapy and have higher rates of remission.
A recent study found that 8.3% of trastuzumab-treated patients developed heart failure, highlighting the need for cardiac monitoring in high-risk breast cancer patients. The study also showed a consistent increase in heart failure risk with age, emphasizing the importance of prioritizing cardiac monitoring for younger patients.
Researchers have developed a novel delivery system using magnetic nanoparticles to target chemotherapy drugs to spinal cord tumors, which are difficult to reach due to the blood-brain barrier. This approach shows promise in treating intramedullary spinal cord tumors with improved survival rates and reduced side effects.
A new study found that Cannabidiol (CBD) significantly improved the survival rate of mice with pancreatic cancer when used alongside chemotherapy. The treatment resulted in nearly tripled survival time compared to those receiving chemotherapy alone.
Australian researchers found that follistatin, a naturally occurring hormone, can enhance the effectiveness of platinum-based chemotherapy and prevent kidney damage in lung cancer patients. The 'two birds, one stone' approach has shown promising results in mouse models.
The TAILORx trial found no benefit from chemotherapy for 70% of women with hormone receptor-positive, HER2-negative breast cancer. Treatment with hormone therapy alone after surgery was as effective as hormone therapy plus chemotherapy in reducing invasive disease-free survival and overall survival.
A new trial presented at ASCO18 shows that PET scans can improve treatment outcomes for esophageal cancer patients. Patients who responded to induction chemotherapy had a median overall survival of 46 months, while those who did not respond had a 27-month median survival, significantly better than previous studies.
A landmark study published in the New England Journal of Medicine found that most breast cancer patients with intermediate scores on a 21-gene test can safely avoid chemotherapy. The study's results have significant implications for doctors and patients, allowing for more personalized treatment options.
A new study examines clinical, functional, and neurophysiological outcomes in 121 long-term childhood cancer survivors. Chemotherapy-induced peripheral neuropathy can be a potentially long-lasting adverse effect of chemotherapy agents.
A clinical trial conducted by Boston Children's Hospital has shown that adding chemotherapy to a treatment regimen including catheterization and surgery can deter abnormal cellular growth in children with pulmonary vein stenosis. The approach led to the stabilization of PVS progression and prevention of further lung damage in 31% of pa...
A targeted 'click-to-release' chemotherapy approach has shown promising results in mice, demonstrating effective anticancer effects against ovarian and colon cancers. The innovative method, developed by Tagworks Pharmaceuticals, releases a large quantity of chemotherapy drug quickly, attacking the tumor cells.
A study found that elderly patients with locally advanced lung cancer who received simultaneous radiotherapy and chemotherapy had worse survival rates compared to younger patients. In contrast, those treated with sequential chemo-radiotherapy or radiotherapy alone had similar survival rates.
Researchers discovered that pre-existing chemoresistant genotypes in tumors can adapt to become fully resistant to chemotherapy, leading to poor overall survival. The study's findings may lead to diagnostic opportunities for detecting resistant clones in TNBC patients before treatment.
Researchers have systematically mapped connections between 625 breast and ovarian cancer genes and nearly every FDA-approved chemotherapy for these cancers. The map reveals new genetic factors that determine the response of tumor cells to common classes of chemotherapy treatment.
Combination therapy of pembrolizumab and chemotherapy significantly improves overall survival and reduces progression risk in patients with non-squamous non-small cell lung cancer. The study found a 51% reduced risk of death compared to chemotherapy alone.
Researchers found that simultaneous chemotherapy and immunotherapy is safe and patients with certain genetic mutations may respond particularly well. The combination approach was shown to boost immune cells in the blood, allaying previous concerns about chemotherapy's impact on immunotherapy.
Researchers discovered a parasite-derived protein, H-IPSE, with potent therapeutic effects on chemotherapy-induced hemorrhagic cystitis in mice. The study found that H-IPSE alters host cell transcription, suggesting a novel approach to treating bladder pain and injury.
A global clinical trial collaboration published in the New England Journal of Medicine found that stage III colon cancer patients can cut their chemotherapy treatments in half after surgery, reducing costs and side effects. For low-risk patients with shallow tumors and few affected lymph nodes, a three-month course is shown to be safe ...
A study found that delivering infused chemotherapy in a physician office resulted in lower healthcare expenditures for commercial health insurers. The study analyzed data from over 283,000 patients who received infused chemotherapy between 2004 and 2014. Delivering chemotherapy at a physician office was associated with lower spending c...
Research identified gene variant ABCC2's role in eliminating chemotherapy, affecting treatment response. Variants associated with high drug elimination rates may lead to reduced treatment effectiveness.
A phase II trial demonstrates the safety and efficacy of de-escalating radiation therapy by 30-35% for patients with HPV-positive disease who respond well to chemotherapy given prior to radiation. Patients experienced excellent survival rates and improved functional outcomes with fewer side effects.
A new optical imaging system uses red and near-infrared light to identify breast cancer patients who are likely to respond to chemotherapy. The system analyzes blood flow dynamics in response to a single breath hold and has been shown to correctly identify responders in 92.3% of patients.
A European Organisation for Research and Treatment of Cancer trial found that combining a 'soft' chemotherapy with antiHER2 therapy is highly active and has low toxicity in older patients with HER2 positive metastatic breast cancer. The regimen resulted in a seven-month longer progression-free survival compared to targeted therapy alone.
Cancer cells can lose multidrug resistance capabilities for days, creating a therapeutic window for chemotherapy. A breakthrough technique uses nanoparticles and near infrared laser treatment to cut off energy supply to efflux pumps, reducing resistance.
Researchers at Southern Methodist University have discovered three drug-like compounds that successfully reverse chemotherapy failure in three of the most commonly aggressive cancers. The compounds were tested on micro-tumors and showed effectiveness against specific cancers, giving hope for developing new drugs to fight cancer.
A large percentage of US small-cell lung cancer patients do not receive standard chemotherapy and radiation treatments, leading to lower overall survival. Patients with federal insurance are more likely to receive chemotherapy but less likely to receive radiation therapy.
Researchers have discovered that experimental diabetes drugs can make cancer cells more vulnerable to traditional chemotherapy agents. The combination of carboplatin and one of the experimental compounds, SR1664, sensitized lung tumor cells and triple-negative breast cancer cells in laboratory models, leading to reduced tumor growth.
Patients with glioblastoma who received TTFields therapy plus chemotherapy had better overall survival and progression-free survival compared to those receiving chemotherapy alone. The study showed significant improvement in treatment outcomes for this aggressive brain tumor.
Researchers at iMM found that certain molecular signals allow cancer cells to survive chemotherapy by altering mitochondrial metabolism. Using VEGF-blocking drugs, they were able to render these cells vulnerable to chemotherapy.
Researchers have found that combining pembrolizumab with high-dose chemotherapy can lead to complete remissions in a significant percentage of relapsed acute myeloid leukemia patients. The study suggests that identifying biomarkers for patients responding to pembrolizumab may improve treatment outcomes.
A study showed that treating younger patients with a combination of chemotherapy and a molecularly targeted drug significantly improves response over traditional chemotherapy alone. The therapy combination resulted in a complete response rate of 37% compared to 20% historically, with ongoing maintenance showing deepened responses.
The combination of chemotherapy and immunotherapy significantly improves progression-free survival in patients with advanced non-squamous NSCLC. The study showed that the addition of atezolizumab to bevacizumab and chemotherapy leads to a median PFS of 8.3 months, compared to 6.8 months with bevacizumab and chemotherapy alone.
Researchers at Carnegie Mellon University developed a new method to improve chemotherapy nanodrug delivery by using an FDA-approved nutrition source. This approach reduces toxic side-effects and increases the amount of drugs reaching tumor cells.
Researchers found that breast cancer tumors impair learning and memory in mice before chemotherapy, suggesting cancer progression causes 'chemo brain' symptoms. After chemotherapy, cancer and drug therapy contribute to cognitive impairment.
A Cornell study reveals that testicular cancer's responsiveness to chemotherapy is due to its stem cells, which are more sensitive to treatment. The research provides new insights into the basis for this phenomenon and may lead to better treatments for other cancers.
Cells can sense and mend damaged DNA caused by certain chemotherapy drugs. Researchers discovered a previously unknown repair complex that targets this type of damage. This finding could lead to more effective chemotherapy treatments by amplifying the killing power of existing drugs.
A study found that proton beam therapy in combination with chemotherapy prior to surgery reduces postoperative heart and lung problems and mortality rates in elderly patients. Researchers followed 571 patients treated with traditional radiation therapy and chemotherapy followed by surgery at Mayo Clinic Cancer Center.
A laboratory-based study discovered that an alcohol aversion drug can reverse chemotherapy resistance in non-small cell lung cancer. The researchers found that the drug, Disulfiram, inhibited ALDH activity, reducing tumour cell growth and killing lung cancer stem cells.
Research led by Dr. Carlos Arteaga has identified potential targets for treating chemotherapy-resistant triple negative breast cancer, including genes MCL1 and MYC. These genes can be targeted with specific drugs to slow or prevent chemotherapy resistance, improving the outlook for this aggressive form of breast cancer.
A phase III trial has confirmed the effectiveness of pelvic radiation as a standard treatment for high-risk stage I-II endometrial cancer. The study found that adjuvant pelvic radiation provided better pelvic control and fewer severe side effects compared to a brachytherapy-chemotherapy combination.
A randomized phase II clinical trial found that adding consolidative stereotactic radiation therapy to chemotherapy significantly increased progression-free survival expectancy nearly tripling it for patients with limited metastatic disease. Treatment-related side effects were similar between the two treatment approaches.
Participating in twice-weekly Tibetan yoga reduced sleep disturbances and improved sleep quality in breast cancer patients undergoing chemotherapy. Women who practiced at least two times a week reported better sleep quality and efficiency over time compared to those practicing less often.
Researchers discover bacteria in pancreatic tumors that metabolize a common chemotherapy drug, rendering it ineffective. The study suggests that targeting these bacteria may offer a new approach to treating pancreatic cancer.